"Designing Growth Strategies is in our DNA"
The U.S. acne treatment market size was valued at USD 4.27 billion in 2021 and is projected to grow from USD 4.50 billion in 2022 to USD 6.12 billion by 2029, exhibiting a CAGR of 4.5% during the forecast period. Based on our analysis, the U.S. market exhibited a decline of 5.8% in 2020 as compared to 2019. The impact of COVID-19 pandemic has been unprecedented and staggering, with acne treatment experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.
Acne is a skin condition that occurs due to the plugging of hair follicles with sebum, oil, dirt, and dead skin cells. According to the published articles, acne is the most common disease in the U.S., it affects an estimated 80% of the total population at some stage of life. The rising prevalence of acne in the U.S. population and the introduction of novel acne drugs to cater to the rising demand are anticipated to propel market growth. For instance, according to the American Academy of Dermatology Association, acne is the most common skin condition in the U.S., affecting up to 50 million Americans annually.
Moreover, growing awareness of treating acne among the affected population and increasing adoption of cosmeceuticals as a supportive treatment are key factors anticipated to increase the demand for products treating acne. This factor, coupled with the increasing patient population suffering from acne, is projected to augment the market growth. Also, adequate reimbursement policies for the treatment of skin conditions, such as psoriasis, and a rising shift toward telemedicine are driving the market growth during the forecast period.
Decline in Patient Visits Amid Pandemic to Negatively Impact Growth of the U.S. Acne Treatment Market
The outbreak of the COVID-19 pandemic had impaired this market. Postponement of most services across treatment of acne in the U.S. and limited availability of skin treatment products were some of the factors leading to a decline in the revenue generated by market players in 2020. For instance, Almirall, S.A. reported a decline of 19.6% in revenue of its dermatology segment during the financial year 2019-2020. Moreover, Johnson and Johnson Services, Inc. reported a decline of 3.1% in revenue of its skin health segment during the financial year 2019-2020.
However, decline in the first half of 2020 was further compensated by a shift of physicians and patients toward telehealth services. Due to these factors, the market is expected to grow, combined with reforms in a few reimbursement policies by the U.S. government for telehealth to support treatment of acne. This factor is expected to reduce the out-of-pocket expenditure, promoting patients to avail treatment for acne, thereby bringing the growth rate back to the pre-pandemic levels.
Request a Free sample to learn more about this report.
Increasing Adoption of Teledermatology by Patients Along with Favorable Government Regulations to Foster Market Growth
Various medical associations, along with the U.S. government, have observed telemedicine as an effective model for diagnosing and treating patients with acne.
Thus, such recommendations by medical organizations and favorable reimbursement for telemedicine have led to a rapid shift of patients toward this model. Also, key market players are engaged in initiatives to introduce in-home diagnostics and consultation in dermatology, which is expected to support market growth. Moreover, specialization in treatment of acne, among other skin conditions, is one of the key trends anticipated to cater to the rising need for personalized medicine in treatment of acne. For instance, in 2021, LifeMD, Inc., a leader in direct-to-patient telehealth services, announced its successful launch of NavaMD. The NavaMD is a personalized teledermatology brand clinic, offering services to patients across all 50 states.
Growing Prevalence of Acne along with Introduction of Novel Acne Products to Surge Demand for Treatment of Acne
The increasing number of patients in the U.S. with several skin disorders, such as inflammatory acne psoriasis, exerts a huge economic burden on the country's healthcare system. The growing prevalence of these conditions is anticipated to surge the demand for treatment products for acne, including retinoids, antibiotics, isotretinoin, and others.
Thus, the increasing economic burden of skin disorders, such as acne vulgaris, has encouraged key companies operating in the market to launch products for the treatment of acne, among other skin-related diseases.
Moreover, initiatives by the government such as favorable reimbursement policies for treatment of acne in the U.S. are improving the flow of patients toward skin therapy. It will subsequently increase the number of patients undergoing treatment and support the market growth in the near future.
Side Effects Associated with Acne Treatment Products Along with High Out of Pocket Expenditure to Restrict Market Growth
The introduction of advanced services such as teledermatology and implementation of various healthcare reforms are some of the key factors driving the market growth in the country. However, frequent side effects in acne treatment with the use of OTC products have been observed across a large patient pool in the U.S.
This factor results in the reduction of patient pool availing acne treatment, which is restricting the market growth.
To know how our report can help streamline your business, Speak to Analyst
Increasing Prevalence of Acne Vulgaris and Convenient Treatment Options to Propel Segmental Growth
According to product type, the market is segmented into retinoids, antibiotics, isotretinoin, and others.
The antibiotics segment held a dominant share in 2021. Some of the major factors attributing to the dominance of this segment are the preference of dermatologists towards prescribing antibiotics and product availability is expected to fuel the segment growth.
The retinoids segment is anticipated to be the fastest-growing segment during the forecast period. The segment's rapid growth is attributed to distinct benefits offered by retinoids, such as reduction in inflammation resulting in the shift of patients towards the segment. Moreover, the underutilization of retinoids in treatment of acne provides the potential for growth of the segment due to the rising demand for treatment of acne during the study period
Limited Side Effects Associated with Topical Treatment to Augment Market Growth
Based on treatment modality, the market is segmented into topical and oral.
The topical segment is projected to grow with the highest CAGR during the study period. Some of the key factors attributed to the highest growth of this segment are fewer incidence of side effects associated with acne treatment alongside the increasing introduction of new products by key manufacturers. Moreover, adequate reimbursement policies for topical products in treatment of acne are anticipated to grow the segment.
On the other hand, the oral segment is expected to grow at a significant CAGR during the forecast period due to higher acceptance of modality among specialists and patients for acne treatment, owing to its clinical superiorities compared to other modes of treatment.
The convenience of oral therapy and physicians' prescription preference are some primary reasons owing to the dominance of the segment.
Presence of Large Patient Pool under Private Insurance Coverage Led to Market Dominance
Based on age group, the market is categorized into 10 to 17, 18 to 44, 45 to 64, and 65 and above.
The 18 to 44 segment held a dominant share of the market in 2021 primarily due to hormonal changes during puberty leading to various acne conditions. Moreover, changing lifestyle in the U.S. is a factor supporting the segment's growth.
Furthermore, the 10 to 17 segment is expected to grow at a high CAGR due to the rising awareness of treatment for acne among teenage patients in the U.S. coupled with key market players focusing on product launches for acne and associated skin treatment conditions.
Among distribution channel, the market is segmented into hospital pharmacies and retail pharmacies.
The retail pharmacy segment dominated the market in 2021 with the lion’s share. The segment's dominance is attributed to the increasing preference of patients due to product choice and brand preference. Moreover, ease of availability through retail model catering to patient needs and a large number of OTC drugs approved for treatment of acne in the U.S. are anticipated to bolster the segment's growth.
Also, the online distribution channel is adopted by most retail pharmacies and holds a significant share in the retail segment. Increasing adoption of teledermatology has given rise to the development of a hybrid online business model that provides consultation, online prescriptions, and home-delivered medication through the same channel. The increasing adoption of online pharmacies and patient convenience is anticipated to effectively cater to the rising demand, thereby supporting the retail segment's growth.
The hospital pharmacies segment is projected to grow over the forecast period, owing to the increasing number of skin specialty departments in leading hospitals and the upsurge in the number of dermatologists practicing through these hospitals.
Presence of Several Market Players Across U.S. Catering to Acne Patients Led to Fragmentation of Market
The market's competitive landscape consists of large, mid-size, and small manufacturers that provide several types of products for the treatment of acne. Major players, such as GALDERMA and Johnson & Johnson Services, Inc., operated as the largest private companies in the U.S. as per the acne treatment market statistics in 2021, owing to their strong direct presence across different states of the U.S. and their robust product portfolio. Moreover, ongoing growth strategies such as partnerships are one of the primary reasons for their dominance in the market.
Also, market players are focusing on product launches to cater to the rising demand for products for treatment of acne and expand their consumer base in the U.S. For instance, in June 2020, Bausch Health Companies Inc. launched ARAZLO Lotion in the U.S. for the topical treatment of acne vulgaris in patients of nine years of age and older.
An Infographic Representation of U.S. Acne Treatment Market
To get information on various segments, share your queries with us
The U.S. acne treatment market research report provides a granular overview of the industry by performing corporate analysis and accurate data. It focuses on key aspects such as growth rates, leading market players, industry trends, product type, treatment modality, and age. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report analyzes and understands several factors that have contributed to the growth of the market in recent years.
ATTRIBUTE | DETAILS |
Study Period | 2018-2029 |
Base Year | 2021 |
Estimated Year | 2022 |
Forecast Period | 2022-2029 |
Historical Period | 2018-2020 |
Unit | Value (USD billion) |
Segmentation | By Product Type, Treatment Modality, Age Group, and Distribution Channel |
Segmentation | By Product Type
|
By Treatment Modality
| |
By Age Group
| |
| By Distribution Channel
|
Fortune Business Insights says that the market stood at USD 4.27 billion in 2021 and is projected to reach USD 6.12 billion by 2029.
In 2021, the market value stood at USD 4.27 billion.
The market will exhibit steady growth at a CAGR of 4.5% during the forecast period (2022-2029).
The antibiotics segment is set to lead the market by product type.
The growing prevalence of acne and the introduction of novel acne products to surge the demand for treatment of acne are the key factors driving the market.
Galderma and Johnson & Johnson Services, Inc. are the top players in the market.